Benefits
Weight loss with hypocaloric diet (Di Pierro 2009)
90-day clinical trial in 100 obese patients comparing 300 mg/day Greenselect Phytosome + hypocaloric diet vs hypocaloric diet alone. The phytosome group lost approximately 3× more weight than the diet-alone group, with significant BMI reduction. Effective demonstration of phytosome bioavailability translating to clinical outcome. Published clinical evidence for the phytosome's weight management application.
Metabolic syndrome improvement (Belcaro 2013)
Controlled registry study in 50 asymptomatic borderline metabolic syndrome subjects with increased oxidative stress. 150 mg/day Greenselect Phytosome for 24 weeks resulted in 68% of treatment-arm subjects exiting the metabolic syndrome profile (vs 20% in controls). Improvements in weight, blood lipid profile, blood pressure, and waist circumference. Published in Drug Discoveries & Therapeutics.
>2× improved EGCG bioavailability
Indena pharmacokinetic comparison: at equal catechin doses (240 mg), Greenselect Phytosome more than doubled peak plasma EGCG concentration vs unformulated Greenselect extract, with sustained higher levels over time. This addresses a real limitation of standard green tea extracts — EGCG's notoriously poor oral bioavailability (<5% in some studies).
Post-menopausal weight and metabolism support
60-day RCT in overweight/Class-I obese post-menopausal sedentary women: 150 mg/day Greenselect Phytosome improved respiratory quotient (favoring fat oxidation), resting energy expenditure, carbohydrate oxidation, and lipid oxidation patterns. Useful for the specific challenge of post-menopausal metabolic dysfunction where conventional weight management often plateaus.
Caffeine-free for evening/sensitive use
≤0.1% caffeine specification (vs 1-5% in non-decaffeinated green tea extracts) makes Greenselect Phytosome suitable for evening dosing schedules and caffeine-sensitive populations. Doesn't disrupt sleep or cause jitters at clinical doses.
Weight maintenance after loss
Specifically studied for the difficult weight-maintenance phase after active weight loss. 3-month post-weight-loss trial with 150 mg twice daily showed better weight maintenance vs placebo. Addresses the well-documented problem of weight regain after caloric restriction.
Mechanism of action
Phytosome bioavailability enhancement
Phytosome® technology complexes EGCG and other catechins with phosphatidylcholine, creating amphipathic structures that improve absorption through the intestinal epithelium. Pharmacokinetic data confirm >2× peak plasma EGCG vs unformulated extract at equal catechin doses.
Catechin-COMT inhibition (norepinephrine extension)
EGCG and other catechins inhibit catechol-O-methyltransferase (COMT), the enzyme that degrades norepinephrine. Extended norepinephrine action prolongs sympathetic-driven thermogenesis and lipolysis. Without caffeine, this effect is milder but free of caffeine-related side effects.
Fat oxidation upregulation
Catechins upregulate fatty acid oxidation enzymes (CPT1, ACO) in skeletal muscle and liver, supporting use of stored fat for energy. Combined with the thermogenic effect, this shifts metabolism toward fat utilization.
Antioxidant protection
Catechins are potent antioxidants — EGCG has one of the highest antioxidant capacities of all polyphenols. Reduces oxidative stress that drives metabolic dysfunction. The Belcaro 2013 metabolic syndrome trial specifically documented improvements in oxidative stress markers alongside the metabolic outcomes.
Clinical trials
90-day clinical trial in 100 obese patients comparing 300 mg/day Greenselect Phytosome + hypocaloric diet vs hypocaloric diet alone.
100 obese patients
90-day clinical trial in 100 obese patients comparing 300 mg/day Greenselect Phytosome + hypocaloric diet vs hypocaloric diet alone. The phytosome group lost approximately 3× more weight than the diet-alone group. Significant BMI reduction documented. Demonstrates phytosome bioavailability translating to improved clinical outcome vs what standard green tea extracts achieve at similar catechin doses.
Controlled registry study in 50 asymptomatic borderline metabolic syndrome subjects with increased oxidative stress.
Clinical population described in trial publication.
Controlled registry study in 50 asymptomatic borderline metabolic syndrome subjects with increased oxidative stress. 150 mg/day Greenselect Phytosome (MonCam formulation) for 24 weeks. Outcome: 68% of treatment-arm subjects exited the metabolic syndrome profile vs 20% in controls. Improvements in weight, blood lipids, blood pressure, and waist circumference. Published in Drug Discoveries & Therapeutics. No side effects reported.